Safety and Immunogenicity of Heterologous Prime-boost Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Infants in a Malaria- Endemic Area.
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2013
At a glance
- Drugs ME-TRAP malaria DNA vaccine Okairos (Primary)
- Indications Malaria
- Focus Adverse reactions
- 26 Sep 2012 Planned End Date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 24 Aug 2012 Planned End Date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 22 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.